What Cemdisiran Could Mean for Myasthenia Gravis Treatment and Patient Safety

Investigational cemdisiran offers a different approach to complement targeting in generalized myasthenia gravis (gMG). In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, explains its mechanism and discusses practical considerations for pharmacists if the therapy is approved.

Habib describes cemdisiran as a small interfering RNA that acts in the liver to reduce production of complement component C5. This differs from existing complement-targeting therapies that act on C5 already present in circulation. He also discusses the potential significance of administration every 12 weeks, which could reduce the burden associated with frequent treatment while providing sustained benefit.

The safety discussion focuses on the role of complement in protection against certain bacterial infections. Habib emphasizes that vaccination can reduce infection risk but does not eliminate it. Patients therefore need counseling that remains relevant even after they have completed recommended vaccinations.

Pharmacists can play an important role in tracking vaccination schedules, which Habib identifies as a practical challenge in clinical care. He also highlights the value of patient safety cards documenting the increased risk of meningococcal infection associated with complement inhibition. Checking that patients carry these cards can support communication during emergency visits or hospital care.

Habib then reviews NIMBLE’s eligibility criteria, explaining that the global study included adults with AChR antibody–positive or LRP4 antibody–positive gMG. He notes that MuSK antibody–positive and seronegative patients were excluded.

Finally, Habib discusses the gap between controlled trial conditions and routine care. Background treatments generally remain stable during clinical trials, whereas clinicians may adjust several therapies in practice. Determining how cemdisiran could fit into treatment decisions will therefore require experience beyond the trial setting. For pharmacists, the interview connects a novel treatment approach with practical responsibilities in patient education and coordination of care while acknowledging questions about its future clinical use.